Big Is Beautiful: Enhanced saRNA Delivery and Immunogenicity by a Higher Molecular Weight, Bioreducible, Cationic Polymer

被引:123
作者
Blakney, Anna K. [1 ]
Zhu, Yunqing [2 ,4 ]
McKay, Paul F. [1 ]
Bouton, Clement R. [1 ]
Yeow, Jonathan [2 ]
Tang, Jiaqing [2 ]
Hu, Kai [1 ]
Samnuan, Karnyart [1 ]
Grigsby, Christopher L. [3 ]
Shattock, Robin J. [1 ]
Stevens, Molly M. [2 ,3 ]
机构
[1] Imperial Coll London, Dept Infect Dis, London W2 1PG, England
[2] Imperial Coll London, Dept Mat, Dept Bioengn, Inst Biomed Engn, London SW7 2AZ, England
[3] Karolinska Inst, Dept Med Biochem & Biophys, S-17165 Stockholm, Sweden
[4] Tong & Univ, Sch Mat Sci & Engn, Shanghai 200092, Peoples R China
基金
英国惠康基金; 欧盟地平线“2020”; 英国工程与自然科学研究理事会; 瑞典研究理事会;
关键词
RNA; replicon; polymer; vaccine; nucleic acid; influenza; HEMAGGLUTINATION INHIBITION ASSAY; MESSENGER-RNA VACCINES; POLY(AMIDO AMINE)S; DISULFIDE LINKAGES; SYSTEMIC DELIVERY; NONVIRAL DELIVERY; IMMUNE-RESPONSES; IN-VIVO; INFLUENZA; CHALLENGES;
D O I
10.1021/acsnano.0c00326
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Self-amplifying RNA (saRNA) vaccines are highly advantageous, as they result in enhanced protein expression compared to mRNA (mRNA), thus minimizing the required dose. However, previous delivery strategies were optimized for siRNA or mRNA and do not necessarily deliver saRNA efficiently due to structural differences of these RNAs, thus motivating the development of saRNA delivery platforms. Here, we engineer a bioreducible, linear, cationic polymer called "pABOL" for saRNA delivery and show that increasing its molecular weight enhances delivery both in vitro and in vivo. We demonstrate that pABOL enhances protein expression and cellular uptake via both intramuscular and intradermal injection compared to commercially available polymers in vivo and that intramuscular injection confers complete protection against influenza challenge. Due to the scalability of polymer synthesis and ease of formulation preparation, we anticipate that this polymer is highly clinically translatable as a delivery vehicle for saRNA for both vaccines and therapeutics.
引用
收藏
页码:5711 / 5727
页数:17
相关论文
共 45 条
  • [41] Vaccine manufacturing: challenges and solutions
    Ulmer, Jeffrey B.
    Valley, Ulrich
    Rappuoli, Rino
    [J]. NATURE BIOTECHNOLOGY, 2006, 24 (11) : 1377 - 1383
  • [42] Endosomal escape pathways for delivery of biologicals
    Varkouhi, Amir K.
    Scholte, Marije
    Storm, Gert
    Haisma, Hidde J.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2011, 151 (03) : 220 - 228
  • [43] Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses
    Vogel, Annette B.
    Lambert, Laura
    Kinnear, Ekaterina
    Busse, David
    Erbar, Stephanie
    Reuter, Kerstin C.
    Wicke, Lena
    Perkovic, Mario
    Beissert, Tim
    Haas, Heinrich
    Reece, Stephen T.
    Sahin, Ugur
    Tregoning, John S.
    [J]. MOLECULAR THERAPY, 2018, 26 (02) : 446 - 455
  • [44] Biomimetic Fluorocarbon Surfactant Polymers Reduce Platelet Adhesion on PTFE/ePTFE Surfaces
    Wang, Shuwu
    Sen Gupta, Anirban
    Sagnella, Sharon
    Barendt, Pamela M.
    Kottke-Marchant, Kandice
    Marchant, Roger E.
    [J]. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2009, 20 (5-6) : 619 - 635
  • [45] Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories
    Zacour, Mary
    Ward, Brian J.
    Brewer, Angela
    Tang, Patrick
    Boivin, Guy
    Li, Yan
    Warhuus, Michelle
    McNeil, Shelly A.
    LeBlanc, Jason J.
    Hatchette, Todd F.
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2016, 23 (03) : 236 - 242